Radiofrequency ablation for stage< IIB non‐small cell lung cancer: Opportunities, challenges, and the road ahead

Q Zhao, J Wang, Y Fu, B Hu - Thoracic Cancer, 2023 - Wiley Online Library
Pulmonary carcinoma represents the second common cancer for human race while its
mortality rate ranked the first all over the world. Surgery remains the primary option for early …

Molecular radiation biology

J Reindl, AM Abrantes, V Ahire, O Azimzadeh… - Radiobiology …, 2023 - Springer
Various exogeneous and endogenous factors constantly cause damages in the
biomolecules within a cell. For example, per day, 10,000–100,000 molecular lesions occur …

Screening and validation of molecular targeted radiosensitizers

H Willers, X Pan, N Borgeaud, I Korovina, L Koi… - International Journal of …, 2021 - Elsevier
The development of molecular targeted drugs with radiation and chemotherapy is critically
important for improving the outcomes of patients with hard-to-treat, potentially curable …

Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead

H Willers, M Krause, C Faivre-Finn… - International Journal of …, 2022 - Elsevier
In many patients with cancer, the dose of radiation therapy (RT) that can be safely
administered is insufficient to achieve high rates of local tumor control and cure. In others …